(Q35977407)

11 August 2017

Combination chemotherapy for intermediate and high grade non-Hodgkin's lymphoma (English)

1 reference

11 August 2017

1 reference

Dhaliwal HS

1

1 reference

11 August 2017

Rohatiner AZ

2

1 reference

11 August 2017

Gregory W

3

1 reference

11 August 2017

Richards MA

4

1 reference

11 August 2017

Johnson PW

5

1 reference

11 August 2017

Whelan JS

6

1 reference

11 August 2017

Gallagher CJ

7

1 reference

11 August 2017

Matthews J

8

1 reference

11 August 2017

Ganesan TS

9

1 reference

11 August 2017

Barnett MJ

10

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 October 1993

1 reference

British Journal of Cancer

11 August 2017

1 reference

11 August 2017

68

1 reference

11 August 2017

4

1 reference

11 August 2017

767-774

1 reference

https://scigraph.springernature.com/pub.10.1038/bjc.1993.425

11 August 2017

0 references

cites work

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968617

The chemotherapy of lymphomas: looking back, moving forward--the Richard and Hinda Rosenthal Foundation award lecture.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968617

Prognostic factors in high and intermediate grade non-Hodgkin's lymphoma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968617

Risk classification as the basis for clinical staging of diffuse large-cell lymphoma derived from 10-year survival data

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968617

Advances in chemotherapy for large cell lymphoma.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968617

Southwest oncology group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968617

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968617

Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968617

Advanced diffuse histiocytic lymphoma, a potentially curable disease

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968617

A new approach to the treatment of advanced high-grade non-Hodgkin's lymphoma--intensive two-phase chemotherapy.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968617

Intensive chemotherapy in aggressive lymphomas: updated results of LNH-80 protocol and prognostic factors affecting response and survival.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968617

Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: a groupwide Southwest Oncology Group study

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968617

Sequential chemotherapy and late intensification for malignant lymphomas of aggressive histologic type.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968617

The m-BACOD combination chemotherapy regimen in large-cell lymphoma: analysis of the completed trial and comparison with the M-BACOD regimen

24 September 2018

1 reference

12 December 2020

Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis

1 reference

12 December 2020

Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs

1 reference

12 December 2020

Prognostic variables in patients with diffuse large-cell lymphoma treated with MACOP-B

1 reference

12 December 2020

The F-MACHOP sequential combination chemotherapy regimen in advanced diffuse aggressive lymphomas: long-term results

1 reference

12 December 2020

Long-term remission in diffuse histiocytic lymphoma treated with combination sequential chemotherapy

1 reference

12 December 2020

The treatment of disseminated non-Hodgkin's lymphoma of unfavourable histology

1 reference

12 December 2020

Predicting therapeutic outcome in patients with diffuse histiocytic lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP)

1 reference

12 December 2020

Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy

1 reference

12 December 2020

Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD)

1 reference

12 December 2020

A multivariate analysis of factors affecting survival in patients with high-grade histology non-Hodgkin's lymphoma

1 reference

12 December 2020

Serum albumin in Hodgkin's disease

1 reference

12 December 2020

MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma

1 reference

12 December 2020

Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience

1 reference

12 December 2020

Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD

1 reference

12 December 2020

Tumor burden assessment and its implication for a prognostic model in advanced diffuse large-cell lymphoma

1 reference

12 December 2020

Prognostic factors in small cell lung cancer: multivariate model based on 778 patients treated with chemotherapy with or without irradiation

1 reference

12 December 2020

Predictive model for prognosis in advanced diffuse histiocytic lymphoma

1 reference

12 December 2020

COPBLAM III: infusional combination chemotherapy for diffuse large-cell lymphoma

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1993.425

1 reference

11 August 2017

1 reference

11 August 2017

1 reference